Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases.
Patients with ischaemic heart disease have high levels of plasminogen activator inhibitor type 1 (PAI-1). These levels can constitute an independent thrombotic risk factor. In addition, PAI-1 synthesis is greater in the atherosclerotic vessels than in the normal vessels and this can also constitute an atherogenic risk factor. There is a good correlation between insulinaemia and PAI-1, but it has not been demonstrated that the circulating level of PAI-1 depends exclusively on insulinaemia. The increased levels of PAI-1 correlate with other coronary risk factors, especially hypertriglyceridaemia, but high PAI-1 levels are also found in normolipaemic patients. Vascular synthesis of PAI-1 can be promoted by high levels of circulating lipoprotein a. Finally, an exercise programme can increase the fibrinolytic activity of heart disease patients towards normal.
Aznar
J
J
Department of Clinical Pathology and Research Centre, La Fe University Hospital, Valencia, Spain.
Estellés
A
A
D001161:Arteriosclerosis / Q000097:blood; D006801:Humans; D017202:Myocardial Ischemia / Q000097:blood* / Q000209:etiology; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood
D017395:Plasminogen Activator Inhibitor 1